N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease

被引:522
|
作者
Kragelund, C
Gronning, B
Kober, L
Hildebrandt, P
Steffensen, R
机构
[1] Univ Copenhagen, Frederiksberg Hosp, Dept Cardiol & Endocrinol, DK-2000 Copenhagen, Denmark
[2] Hillerod Univ Hosp, Dept Cardiol, Copenhagen, Denmark
[3] Rigshosp, Dept Cardiol, Copenhagen, Denmark
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2005年 / 352卷 / 07期
关键词
D O I
10.1056/NEJMoa042330
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The level of the inactive N-terminal fragment of pro-brain (B-type) natriuretic peptide (BNP) is a strong predictor of mortality among patients with acute coronary syndromes and may be a strong prognostic marker in patients with chronic coronary heart disease as well. We assessed the relationship between N-terminal pro-BNP (NT-pro-BNP) levels and long-term mortality from all causes in a large cohort of patients with stable coronary heart disease. METHODS: NT-pro-BNP was measured in baseline serum samples from 1034 patients referred for angiography because of symptoms or signs of coronary heart disease. The rate of death from all causes was determined after a median follow-up of nine years. RESULTS: At follow-up, 288 patients had died. The median NT-pro-BNP level was significantly lower among patients who survived than among those who died (120 pg per milliliter [interquartile range, 50 to 318] vs. 386 pg per milliliter [interquartile range, 146 to 897], P<0.001). Patients with NT-pro-BNP levels in the highest quartile were older, had a lower left ventricular ejection fraction (LVEF) and a lower creatinine clearance rate, and were more likely to have a history of myocardial infarction, clinically significant coronary artery disease, and diabetes than patients with NT-pro-BNP levels in the lowest quartile. In a multivariable Cox regression model, the hazard ratio for death from any cause for the patients with NT-pro-BNP levels in the fourth quartile as compared with those in the first quartile was 2.4 (95 percent confidence interval, 1.5 to 4.0; P<0.001); the NT-pro-BNP level added prognostic information beyond that provided by conventional risk factors, including the patient's age; sex; family history with respect to ischemic heart disease; the presence or absence of a history of myocardial infarction, angina, hypertension, diabetes, or chronic heart failure; creatinine clearance rate; body-mass index; smoking status; plasma lipid levels; LVEF; and the presence or absence of clinically significant coronary artery disease on angiography. CONCLUSIONS: NT-pro-BNP is a marker of long-term mortality in patients with stable coronary disease and provides prognostic information above and beyond that provided by conventional cardiovascular risk factors and the degree of left ventricular systolic dysfunction.
引用
收藏
页码:666 / 675
页数:10
相关论文
共 50 条
  • [21] Percutaneous coronary revascularization reduces plasma N-terminal pro-B-type natriuretic peptide concentration in stable coronary artery disease
    McClure, Samuel J.
    Gall, Scott
    Schechter, Clyde B.
    Kearney, Mark
    Zaman, Azfar G.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (25) : 2394 - 2397
  • [22] The effect of percutaneous coronary revascularization on plasma N-terminal pro-B-type natriuretic peptide levels in stable coronary artery disease
    Gupta, Amit
    Beig, Jahangir Rashid
    Tramboo, Nisar A.
    Afroze, Dil
    Hafeez, Imran
    Rather, Hilal A.
    INDIAN HEART JOURNAL, 2018, 70 (02) : 282 - 288
  • [23] Relation of N-Terminal Pro-B-Type Natriuretic Peptide With Diastolic Function in Hypertensive Heart Disease
    Uraizee, Imran
    Cheng, Susan
    Hung, Chung-Lieh
    Verma, Anil
    Thomas, James D.
    Zile, Michael R.
    Aurigemma, Gerard P.
    Solomon, Scott D.
    AMERICAN JOURNAL OF HYPERTENSION, 2013, 26 (10) : 1234 - 1241
  • [24] Prognostic value of N-terminal pro-B-type natriuretic peptide in adults with congenital heart disease
    Baggen, V. J. M.
    Van den Bosch, A. E.
    Eindhoven, J. A.
    Cuypers, J. A. A. E.
    Witsenburg, M.
    De Waart, M.
    Boersma, E.
    Roos-Hesselink, J. W.
    EUROPEAN HEART JOURNAL, 2016, 37 : 574 - 574
  • [25] N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes
    Ezekowitz, Justin A.
    O'Connor, Christopher M.
    Troughton, Richard W.
    Alemayehu, Wendimagegn G.
    Westerhout, Cynthia M.
    Voors, Adriaan A.
    Butler, Javed
    Lam, Carolyn S. P.
    Ponikowski, Piotr
    Emdin, Michele
    Patel, Mahesh J.
    Pieske, Burkert
    Roessig, Lothar
    Hernandez, Adrian F.
    Armstrong, Paul W.
    JACC-HEART FAILURE, 2020, 8 (11) : 931 - 939
  • [26] Role Of N-Terminal Pro-B-Type Natriuretic Peptide In Diagnosis and Prognosis Of Chinese Patients with Stable Coronary Artery Disease
    Wong, C. Y.
    Wong, B. Y.
    Ng, S. Y.
    Chan, M. C.
    Iu, Y. P.
    Chan, A. O. K.
    Lee, K. Y.
    Shek, C. C.
    Chan, K. T.
    Ho, K. C.
    Chiang, C. S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (13) : B42 - B43
  • [27] N-Terminal Pro-B-Type Natriuretic Peptide and Incident CKD
    Sasaki, Takaya
    Oishi, Emi
    Nagata, Takuya
    Sakata, Satoko
    Chen, Sanmei
    Furuta, Yoshihiko
    Honda, Takanori
    Yoshida, Daigo
    Hata, Jun
    Tsuboi, Nobuo
    Kitazono, Takanari
    Yokoo, Takashi
    Ninomiya, Toshiharu
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (04): : 976 - 985
  • [28] N-terminal pro-B-type natriuretic peptide and inducible ischemia in patients with coronary heart disease from the heart and soul study
    Singh, H. S.
    Bibbins-Domingo, K.
    Sadia, A.
    Whooley, M. A.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2007, 22 : 54 - 54
  • [29] N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease
    Alves, Mariana
    Caldeira, Daniel
    Reimao, Sofia
    Ferro, Jose M.
    Ferreira, Joaquim J.
    MOVEMENT DISORDERS, 2020, 35 (10) : 1886 - 1887
  • [30] N-terminal-pro brain-type natriuretic peptide and long-term mortality in stable coronary heart disease: relation to diabetes status
    Kragelund, C
    Kober, L
    Faber, J
    Hildebrandt, R
    Steffensen, R
    EUROPEAN HEART JOURNAL, 2004, 25 : 459 - 459